Document:

Exhibit 10.1

 

FIRST AMENDMENT TO ASSIGNMENT AGREEMENT

 

THIS FIRST AMENDMENT
TO ASSIGNMENT AGREEMENT (this “Amendment”), dated June 7, 2019, is entered into by and between Xenetic
Biosciences, Inc., a Nevada corporation (“Buyer”), and OPKO PHARMACEUTICALS, LLC (“OPKO”).

 

RECITALS

 

WHEREAS, Buyer
and OPKO previously entered into that certain Assignment Agreement, dated as of March 1, 2019 (the “Assignment Agreement”);

 

WHEREAS, pursuant
to Section 9.09 of the Assignment Agreement, the Assignment Agreement may be amended, modified or supplemented by an agreement
in writing signed by Buyer and OPKO; and

 

WHEREAS, Buyer
and OPKO desire to amend the Assignment Agreement by entering into this Amendment.

 

NOW, THEREFORE,
in consideration of the premises, the mutual covenants set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1.       Definitions.
Capitalized terms used herein and not defined herein shall have the meaning ascribed to such terms as set forth in the Assignment
Agreement and all references to Sections shall mean the Sections of the Assignment Agreement unless reference is made to another
document.

 

2.       Amendment
to Assignment Agreement. The Assignment Agreement is hereby amended as follows:

 

(a)       Section
2.02. Section 2.02 is deleted in its entirety and amended and restated as follows:

“Section
2.02 Consideration.

 

(a) Purchase
Price. As consideration for the transactions contemplated herein, Buyer shall pay Two Million Six Hundred Twenty Five Thousand
(2,625,000) shares of Buyer Common Stock (the “Purchase Price,” and such shares of Buyer Common Stock, the “Transaction
Shares”), regardless of the trading price per share of the Transaction Shares at the time of Closing (subject to the
provisions contained in (b) below), One Million Nine Hundred Sixty Eight Thousand Seven Hundred and Fifty (1,968,750) of which
shall be issued to Company, and Six Hundred Fifty Six Thousand Two Hundred Fifty (656,250) of which Company designates Buyer to
issue directly to Scripps.

 

(b) Adjustments.
Notwithstanding anything contained herein to the contrary, if at any time during the period between the date of this Agreement
and the Closing Date, any change in the outstanding shares of Buyer Common Stock shall occur by reason of any reclassification,
recapitalization, stock split, reverse split, subdivision or combination, exchange or readjustment of shares, or any stock dividend
thereon with a record date during such period, the number of shares of Buyer Common Stock to be issued pursuant to this Agreement
due to any such occurrence described above as the aggregate consideration for the Transaction Shares payable to Company and Scripps
pursuant to Section 2.02(a) of this Agreement shall be correspondingly adjusted.”

 

3.       Assignment
Agreement Otherwise Unchanged. Except as expressly provided herein, the Assignment Agreement shall remain unchanged and in
full force and effect. Each reference to “this Agreement” or “the Assignment Agreement” and words of similar
import in the Assignment Agreement and in the agreements and other documents contemplated by the Assignment Agreement shall be
a reference to the Assignment Agreement, as amended hereby, and as the same may be further amended, restated, supplemented and
otherwise modified and in effect from time to time.

 

4.       Ratification.
In all respects not inconsistent with this Amendment, Buyer and OPKO hereby ratify and affirm the Assignment Agreement as amended
hereby.

 

5.       Miscellaneous.
This Amendment shall be binding upon and inure to the benefit of each party to the Assignment Agreement and its successors and
permitted assigns. The interpretation and construction of this Amendment, and all matters relating hereto, shall be governed by
the laws of the State of Delaware applicable to agreements executed and to be performed solely within such State and without regard
to the conflict of laws rules thereof. The headings in this Amendment are for reference only and shall not affect the meaning or
interpretation of this Amendment. This Amendment may be executed in counterparts, each of which is deemed an original, but all
of which constitute one and the same instrument. Delivery of an executed counterpart of this Amendment electronically, via email
or .pdf, or by facsimile shall be effective as delivery of an original executed counterpart of this Amendment.

 

[Signature Page Follows]

 

 

    	 	1	 

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Amendment as of the date and year first set forth above.

 

 

 

	 	BUYER:
	 	 
	 	XENETIC BIOSCIENCES, INC.
	 	 
	 	 
	 	By: /s/ Jeffrey F. Eisenberg                       
	 	Name: Jeffrey F. Eisenberg
	 	Title:   Chief Executive Officer
	 	 
	 	 
	 	 
	 	OPKO:
	 	 
	 	OPKO PHARMACEUTICALS, LLC
	 	 
	 	By: /s/ Steven D. Rubin                             
	 	Name: Steven D. Rubin
	 	Title:   Executive Vice President

 

 

 

 

 

    	 	2EX-10.1

 Exhibit 10.1 

G1 THERAPEUTICS, INC. 

AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 

The Board of Directors of G1 Therapeutics, Inc. (the “Company”) has approved the following Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) which establishes compensation to be paid to non-employee directors of the Company, effective as of
June 12, 2019 (the “Effective Date”), to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors. 

Applicable Persons 
 This Policy shall apply to each
director of the Company who is not an employee of the Company or any Affiliate (each, a “Non-Employee Director”). “Affiliate” shall mean an entity which is a direct or
indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal Revenue Code of 1986, as amended. 
 Stock
Option Grants 
 All stock option amounts set forth herein shall be subject to automatic adjustment in the event of any stock split or other
recapitalization affecting the Company’s common stock. 
 Annual Stock Option Grants 

Annually, each Non-Employee Director shall be granted a non-qualified stock
option to purchase 20,000 shares of the Company’s common stock under the Company’s 2017 Employee, Director and Consultant Equity Incentive Plan (the “Stock Plan”) on the date of the first meeting of the Board of Directors
held following the Company’s annual meeting of stockholders. 
 Initial Stock Option Grant for Newly Appointed or Elected Directors 

Each new Non-Employee Director shall be granted a non-qualified stock option to
purchase 40,000 shares of the Company’s common stock under the Stock Plan at the first regularly scheduled meeting of the Board of Directors on or after his or her initial appointment or election to the Board of Directors. 

Initial Stock Option Grant for Newly Appointed or Elected Chairperson 

Each new Non-Employee Director who shall serve as Chairperson of the Board of Directors shall be granted a non-qualified stock option to purchase 100,000 shares of the Company’s common stock under the Stock Plan at the first regularly scheduled meeting of the Board of Directors on or after his or her initial
appointment as Chairperson of the Board of Directors. This grant is in addition to the Annual Stock Option Grant. 
 Terms for All Option Grants 

Unless otherwise specified by the Board of Directors or the Compensation Committee at the time of grant, all options granted under this Policy shall
(i) have an exercise price equal to the fair market value of the Company’s common stock as determined in the Stock Plan on the grant date; (ii) terminate ten years after the grant date; (iii) vest 100% upon the consummation of a change-in-control; and (iv) contain such other terms and conditions as set forth in the form of option agreement approved by the Board of Directors or the Compensation
Committee prior to the grant date. Subject to the continued service of each Non-Employee Director and unless otherwise specified by the Board of Directors or the Compensation Committee at the time of grant,
each annual stock option grant shall vest on the first anniversary of the date of grant and each initial stock option grant shall vest in equal monthly installments following the date of grant until the third anniversary of the grant date. 

 Annual Fees 

Each Non-Employee Director serving on the Board of Directors and the Audit Committee, Compensation Committee and/or
Nominating and Governance Committee, as applicable, shall be entitled to the following annual amounts (the “Annual Fees”): 
  

					
	 Board of Directors or 
Committee of Board of

Directors
	  	Annual Retainer
Amount for Member	  	Annual Retainer
Amount for Chair
(total)
	 Board of Directors
	  	$40,000	  	$70,000
	 Audit Committee
	  	$10,000	  	$30,000
	 Compensation Committee
	  	$  7,500	  	$22,500
	 Nominating and Governance Committee
	  	$  5,000	  	$15,000

 Except as otherwise set forth in this Policy, all Annual Fees shall be paid for the period from January 1 through
December 31 of each year. Such Annual Fees shall be paid in cash. 
 Payments 

Payments payable to Non-Employee Directors shall be paid quarterly in arrears promptly following the end of each fiscal
quarter, provided that (i) the amount of such payment shall be prorated for any portion of such quarter that such director was not serving on the Board of Directors or a committee and (ii) no fee shall be payable in respect of any period
prior to the date such director was elected to the Board of Directors or a committee. 
 Expenses 

Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each Non-Employee Director
shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board of Directors and committees
thereof or in connection with other business related to the Board of Directors. 
 Amendments 

The Compensation Committee shall periodically review this Policy to assess whether any amendments in the type and amount of compensation provided herein should
be made and shall make recommendations to the Board of Directors for its approval of any amendments to this Policy.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]